What is claimed is

1. 5,11-Dihydrodiaryl[b,e][1,4]oxazepine derivatives represented by the following general formula [I], stereoisomers thereof, pharmacologically acceptable salts thereof, and hydrates or solvates thereof:



[I]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; R^1 to R^8 may be the same or different from one another and they each represent a halogen atom or hydrogen atom, R^9 to R^{13} may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hydroxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form $-O(CH_2)nO-$ group wherein n is 1, 2 or 3; A represents

CH_2, CHOH, CO or O; B represents CH_2, CHOH or CO; or A-B represents CH=CH, D represents CH_2, CH_2-CH_2 or CH_2-CH_2-CH_2 or B-D represents CH_2; X and Z are bonded together to form CH_2-CH_2 or CH_2-CH_2-CH_2 and, in this case, Y represents a hydrogen atom; or Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2.CH_2.CH_2-CH_2 and, in this case, X represents a hydrogen atom; and when X and Z, and Y and Z are not bonded together, X and Y each represent a hydrogen atom and Z represents a lower alkyl group;

provided that when any of R^9 to R^{13} represents a cyclic amino group of the following formula [E], R^1 to R^8 may be a halogen atom or hydrogen atom but when none of R^9 to R^{13} is a cyclic amino group of formula [E], one or two of R^1 to R^8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

2. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to claim 1 wherein rings G and J are both benzene rings.

3. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers,

pharmacologically acceptable salts thereof or hydrates thereof according to claim 1 wherein either ring G or J is pyridine ring and the other is benzene ring.

4. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 3 wherein ring K is benzene ring.

5. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 3 wherein ring K is pyridine ring, pyrimidine ring, pyrazine ring or pyridazine ring.

6. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to claim 1 wherein rings G, J and K are benzene rings.

7. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 6 wherein X and Z are bonded together to form CH_2-CH_2 or CH_2-CH_2-CH_2 and Y represents a hydrogen atom.

8. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 6 wherein Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 and X represents a hydrogen atom.

9. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 6 wherein X and Y are each a hydrogen atom and Z represents a lower alkyl group.

10. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives,

stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 9 wherein either or both of R^{10} and R^{11} are methoxyl group or R^{10} and R^{11} together form methylenedioxyl group, and R^9, R^{12} and R^{13} are each a hydrogen atom.

11. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 9 wherein R^{11} is methoxyl group, and R^9, R^{10}, R^{12} and R^{13} are each a hydrogen atom.

12. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 9 wherein either R^{10} or R^{11} is amino group, a lower alkylamino group, a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, and the other is a hydrogen atom.

13. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 9 wherein either R^{10} or R^{11} is a cyclic amino group represented by formula [E] and the other is a hydrogen atom.

14. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to claim 13 wherein all of R^1 to R^8 are a hydrogen atom.

15. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 13 wherein one of R^1 to R^8 is fluorine atom or chlorine atom and the other is a hydrogen atom.

16. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 13 wherein one of R^2, R^3, R^6 and R^7 is fluorine atom or chlorine atom and others are each a hydrogen atom.

17. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers, pharmacologically acceptable salts thereof or hydrates thereof according to any of claims 1 to 16 wherein A and B-D are both CH_2.

18. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, pharmacologically acceptable salts thereof or hydrates thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of R.

19. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, pharmacologically acceptable salts thereof or hydrates thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of S.

20. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, pharmacologically acceptable salts thereof or hydrates thereof according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of R.

21. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, pharmacologically acceptable salts thereof or hydrates thereof according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of S.

22. A pharmaceutical composition containing any of 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers thereof,

pharmacologically acceptable salts thereof and hydrates thereof according to any of claims 1 to 5 and 7 to 21 as the active ingredient.

23. A pharmaceutical composition containing any of 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers thereof, pharmacologically acceptable salts thereof and hydrates thereof according to claim 6 as the active ingredient.

24. A pharmaceutical composition for treating or preventing functional diseases of digestive tracts, containing any of 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers thereof, pharmacologically acceptable salts thereof and hydrates thereof according to any of claims 1 to 21 as the active ingredient.

25. The pharmaceutical composition for treating or preventing the diseases according to claim 24, wherein the functional diseases of digestive tracts are diseases of gastrointestinal motor functions.

26. 5,11-Dihydrodiaryl[b,e][1,4]oxazepine derivatives represented by the following general formula [XV], stereoisomers thereof and salts thereof:



[XV]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; R^1 to R^8 may be the same or different from one another and they each represent a halogen atom or a hydrogen atom, R^9 to R^{13} may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hy6droxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form $-O(CH_2)nO-$ group wherein n is 1, 2 or 3; L_1 represents CH_2, CHOH or O; L_2 represents CH_2, CHOH, CH_2-CH_2, CHOH-CH_2, CH_2-CH_2-CH_2 or CHOH-CH_2-CH_2; or L_1 and L_2 are bonded together to form CH_2 , CHOH or CH=CH, Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 or when Y and Z are not bonded together, Y represents a hydrogen atom and Z represents a lower alkyl group;

provided that when any of R^9 to R^{13} represents a cyclic amino group of the following formula [E], R^1 to R^8 may be a halogen atom or hydrogen atom

but when none of R^9 to R^{13} is a cyclic amino group of formula [E], one or two of R^1 to R^8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

27. Amide derivatives of general formulae [XVI], stereoisomers thereof and salts thereof:



[XVI]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; R^1 to R^8 may be the same or different from one another and they each represent a halogen atom or hydrogen atom, R^9 to R^{13} may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hydroxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form $-O(CH_2)nO-$ group wherein n is 1, 2 or 3; L_1 represents CH_2, CHOH or O; L_2 represents CH_2, CHOH, CH_2-CH_2, CHOH-CH_2, CH_2-CH_2-CH_2 or CHOH-CH_2-CH_2; or L_1 and L_2 are bonded together to form CH_2, CHOH or CH=CH, Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 or when Y and Z are not bonded together, Y represents a hydrogen atom and Z represents a lower alkyl group;

provided that when any of R^9 to R^{13} represents a cyclic amino group of the following formula [E], R^1 to R^8 may be a halogen atom or hydrogen atom but when none of R^9 to R^{13} is a cyclic amino group of formula [E], one or two of R^1 to R^8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or

nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

28. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers thereof and salts thereof according to claim 26, wherein R^1 to R^8 may be the same or different from one another and they each represent fluorine atom, chlorine atom or a hydrogen atom, L_1-L_2 represents CH_2 or CH_2-CH_2, Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2.

29. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers and salts thereof according to claim 28 wherein rings G, J and K are benzene rings.

30. The amide derivatives, stereoisomers thereof and salts thereof according to claim 27, wherein R^1 to R^8 may be the same or different from one another and they each represent fluorine atom, chlorine atom or a hydrogen atom, L_1-L_2 represents CH_2 or CH_2-CH_2 and Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2.

31. The amide derivatives, stereoisomers and salts thereof according to claim 30 wherein rings G, J and K are benzene rings.

32. The 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivatives, stereoisomers and salts thereof according to claim 29, wherein R^9 to R^{13} may be the same or different from one another and they each represent a hydrogen atom, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group.

33. The amide derivatives, stereoisomers and salts thereof according to claim 31, wherein R^9 to R^{13} may be the same or different from one another

and they each represent a hydrogen atom, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group.

34. (R)-{[2-(3-Chloro-5,11-dihydrodibenzo[b,e][1,4]oxazepine-5-carbonyl)pyrrolidine]-1-yl}-2-(4-dimethylaminophenyl)ethanone, and stereoisomers and salts thereof.

35. (R)-1-[(4-Dimethylaminophenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromo-4-chlorobenzyloxy)phenyl]amide, and stereoisomers and salts thereof.

36. (R)-{[2-(2-Fluoro-5,11-dihydrodibenzo[b,e][1,4]oxazepine-5-carbonyl)pyrrolidine]-1-yl}-2-(4-pyrrolidinophenyl)ethanone, and stereoisomers and salts thereof.

37. (R)-1-[(4-Pyrrolidinophenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromo-5-fluorobenzyloxy)phenyl]amide, and stereoisomers and salts thereof.